A study of MGD014 for the treatment of HIV infections

Trial Profile

A study of MGD014 for the treatment of HIV infections

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs MGD 014 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2017 According to a company media release, MacroGenics' IND submission for MGD014 has been cleared by the US FDA and the Company anticipates that a first patient will be dosed in early 2018.
    • 05 Sep 2017 According to a MacroGenics media release, the company has submitted an IND for MGD014.
    • 11 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top